Affimed Reports Third Quarter 2022 Financial Results and Highlights Recent Clinical and Corporate Progress

November 15, 2022

https://www.globenewswire.com/news-release/2022/11/15/2555906/0/en/Affimed-Reports-Third-Quarter-2022-Financial-Results-and-Highlights-Recent-Clinical-and-Corporate-Progress.html

HEIDELBERG, Germany, Nov. 15, 2022 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq:AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results for the third quarter ended September 30, 2022 and provided an update on clinical and corporate progress.

Read more at globenewswire.com

Related news for (AFMD)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.